TPTX News and Press, Turning Point Therapeutics Inc. From 09/03/19

In TKI-naïve ROS1+ NSCLC Patients, Overall Response Rate by Blinded Review Improved to 91 Percent; Median Duration of Response Not Yet Mature with 20.1 months of Median Follow-Up Improved Results in Heavily Pretreated ROS1+ NSCLC Patients, with First Confirmed Responses in P...

SAN DIEGO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in the 2019 Wells Fargo Healthcare...

Turning Point Therapeutics, Inc. (TPTX) Q2 2019 Earnings Conference Call August 06, 2019, 16:30 ET Company Participants Jim Mazzola - SVP, Communication & IR Athena Countouriotis - President & CEO Brian Baker - VP, Finance & Administration Conference Call Participa...

Turning Point Therapeutics (NASDAQ: TPTX ): Q2 GAAP EPS of -$0.70 misses by $0.20 . More news on: Turning Point Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

FDA Accepts Repotrectinib Recommended Phase 2 Dose Regimen for Registrational TRIDENT-1 Study Two Abstracts Selected for Presentation at the European Society for Medical Oncology (ESMO) Annual Congress Highlighting Clinical Data for Repotrectinib in ROS1 and TRK patients, and Pre...

SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session a...

SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1 clinical study of patients with advanced solid tumors harboring genetic ...

SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today named Yi Larson as executive vice president and chief financial officer, effective Aug. 26. Ms. Larson joi...

SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the appointment of Carol Gallagher, Pharm.D. to its board of directors. Dr. Gallagher brings nea...

SAN DIEGO, July 22, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, will report second quarter financial results following the close of U.S. financial markets on Aug. 6 and host a ...